Additionally, breakthroughs include inhibitors targeting ALK, ROS1, BRAF, RET, and NTRK, alongside the recent integration of immune checkpoint pathway inhibitors in both second-line and front-line treatments for NSCLC.7It is crucial to highlight that these immunotherapy strategies necessitate the alignment of known antigens or pathways with specialized antibodies. This evidence concerns the gene ALK and non-small cell lung carcinoma.